

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Service Category:

- | | |
|--|---|
| ☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures | ☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Other: Part B Drugs |
|--|---|

Service Description:

This document addresses the use of **Telisotuzumab vedotin-tllv (Emrelis)**, a drug approved by the Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [$\geq 50\%$ of tumor cells with strong (3+) staining] who have received a prior systemic therapy (prior therapies in the trial included chemotherapy, tyrosine kinase inhibitors, or immune checkpoint inhibitors).

Background Information:

EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate. The recommended dosage of Emrelis is 1.9 mg/kg (up to a maximum of 190 mg for patients greater than or equal to 100 kg) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.

Avoid use of Emrelis in patients with moderate or severe hepatic impairment (total bilirubin $> 1.5 \times$ ULN and any AST). Patients with moderate or severe hepatic impairment are likely to have increased exposure to MMAE, which may increase the risk of adverse reactions. Emrelis has not been studied in patients with moderate or severe hepatic impairment. No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin $\leq$ ULN and AST $>$ ULN or total bilirubin $>$ ULN and $\leq 1.5 \times$ ULN and any AST).

Definitions and Measures

- Adenocarcinoma: Cancer originating in cells that line specific internal organs and that have gland-like (secretory) properties.
- Disease Progression: Cancer that continues to grow or spread.
- ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:
 - 0 = Fully active, able to carry on all pre-disease performance without restriction
 - 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light housework, office work
 - 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
 - 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
 - 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
 - 5 = Dead
- Line of Therapy:

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

- First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.
- Locally advanced cancer: Cancer that has spread only to nearby tissues or lymph nodes.
- Maintenance therapy: Designed to maintain a condition to prevent a relapse.
- Malignant: Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.
- Metastasis: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
- Mutation: A permanent, transmissible change in genetic material.
- Non-small cell lung cancer: A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.
- One line of therapy: Single line of therapy.
- Primary refractory disease: Cancer that does not respond at the beginning of treatment; may also be called resistant disease.
- Primary treatment: The first treatment given for a disease. It is often part of a standard set of treatments, such as surgery followed by chemotherapy and radiation. Also called first-line therapy, induction therapy, and primary therapy.
- Progressive Disease (PD): Cancer is growing, spreading, or getting worse. Refractory Disease: Illness or disease that does not respond to treatment.
- Relapses or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.
- Stable disease: Cancer that is not decreasing or increasing in extent or severity.
- Targeted biologic agent: A newer type of drug developed specifically to target genetic changes in cells that cause cancer. It works differently than standard chemotherapy drugs, often with different side effects.

Approved Indications

- A. For the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [$\geq 50\%$ of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Other Uses

- A. Subsequent systemic therapy as a single agent for recurrent, advanced, or metastatic non-squamous NSCLC in individuals with HGF receptor/c-Met $\geq 50\%$ by IHC 3+, EGFR wild-type disease, and ECOG performance status 0–2. [NCCN 2A].

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Telisotuzumab vedotin-tllv (Emrelis™)

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

Requests for Emrelis (telisotuzumab vedotin-tllv) may be approved if the following criteria are met:

- i. Individual has a diagnosis of Non-small cell lung cancer (NSCLC) (Label, NCCN 2A); **AND**
- ii. Individual has recurrent, locally advanced, or metastatic non-squamous NSCLC; **AND**
- iii. Individual has EGFR wild-type disease; **AND**
- iv. Individual has high c-Met/MET protein expression [$\geq 50\%$ of tumor cells with strong (IHC 3+) staining]; **AND**
- v. Individual has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; **AND**
- vi. Individual has received a prior systemic therapy; **AND**
- vii. Individual is using Emrelis as subsequent systemic therapy as a single agent.

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of *Telisotuzumab vedotin-tllv (Emrelis)* therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. The following information should be submitted for reauthorization:
 - A. A current oncology note documenting the patient's response to treatment showing no progression of disease.
 - B. Current imaging studies and other objective measures, as appropriate, showing no progression of disease when compared with previous results.

C. Authorization Duration

- i. Initial Approval Duration: Up to 6 months
- ii. Reauthorization Approval Duration: Up to 6 months

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Requests for Emrelis (telisotuzumab vedotin-tllv) may not be approved for the following:

- i. Individual has moderate or severe hepatic impairment (total bilirubin > 1.5 x ULN and any AST); **OR**
- ii. When the above criteria are not met and for all other indications.

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Vials
EMRELIS™ (telisotuzumab vedotin-tllv)-for injection	- Intravenous Solution Reconstituted 100MG Vial - Intravenous Solution Reconstituted 20MG Vial
Dosage	
1.9 mg/kg (up to a maximum of 190 mg for patients greater than or equal to 100 kg) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity	

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
C33	Malignant neoplasm of trachea
C34.00 – C34.92	Malignant neoplasm of bronchus and lung
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

HCPCS Codes:

Codes	Description
J9326	Injection Telisotuzumab Vedotin-Tllv 1 Mg

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Reference Information:

1. AbbVie Inc. (2025). EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous use: Prescribing information. Revised May 2025. Accessed April 29, 2026.
https://www.rxabbvie.com/pdf/emrelis_pi.pdf
2. Clinicaltrials.gov. National Library of Medicine. Available at: <https://clinicaltrials.gov/>. Accessed on May 27, 2025.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: May 27, 2025.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on May 27, 2025.
 - a. Non-Small Cell Lung Cancer. V5.2026. Revised March 13, 2026

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Medical Policy

Utilization Management and Clinical Medical Policy

Policy Name: Telisotuzumab vedotin-tllv (Emrelis)	Policy Number: MP-RX- FP-175-25	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 7/21/2025 Last Review Date: 7/1/2026	Effective Date: 7/1/2026 Frequently Revision: Annual
--	---	---	---	---

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Added Emrelis drug class, FDA approved indications, and other uses to the background information. Incorporated NCCN Category 2A recommendation for use as subsequent systemic therapy as a single agent in recurrent, advanced, or metastatic non-squamous NSCLC. Coding reviewed: added ICD-10 codes: C33, C34.00 – C34.92, and Z85.118. Updated references list and incorporated new policy template.	6/19/2026	7/1/2026
Select Review	Coding reviewed: J9326 added.	N/A	N/A
Policy Inception	Elevance Health's Medical Policy adoption.	7/21/2025	7/21/2025